Skip to main content
Journal cover image

Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.

Publication ,  Journal Article
George, DJ; Mohamed, AF; Tsai, J-H; Karimi, M; Ning, N; Jayade, S; Botteman, M
Published in: Cancer Med
March 2023

BACKGROUND: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration-resistant prostate cancer (mCRPC) can facilitate shared-decision making for optimal management. This study sought to elicit patient preferences for mCRPC treatments in the US. METHODS: We conducted a cross-sectional survey using the discrete-choice experiment method. Participants were asked to state their choices over successive sets of treatment alternatives, defined by varying levels of treatment attributes: overall survival (OS), months until patients develop a fracture or bone metastasis, likelihood of requiring radiation to control bone pain, fatigue, nausea, and administration (i.e., oral/IV injection/IV infusion). Using mixed logit models, we determined the value (i.e., preference weights) that respondents placed on each attribute. Relative attribute importance (RAI) and marginal rates of substitution (MRS) were calculated to understand patients' willingness to make tradeoffs among different attributes. RESULTS: The final data set numbered 160 participants, with a mean age of 71.6 years old and a mean of 8.96 years since prostate cancer diagnosis. Participants' treatment preferences were as follows: OS (RAI: 31%), bone pain control (23%), nausea (16%), delaying fracture or bone metastasis (15%), fatigue (11%), and administration (3%). The MRS demonstrated that respondents were willing to trade 1.9 months of OS to eliminate moderate nausea and 3.3 months of OS for a reduction in fatigue from severe to mild. CONCLUSIONS: Improving OS is the highest priority for patients with mCRPC, but they are willing to trade some survival to reduce the risk of requiring radiation to control bone pain, delay a fracture or bone metastasis, and experience less severe nausea and fatigue.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Med

DOI

EISSN

2045-7634

Publication Date

March 2023

Volume

12

Issue

5

Start / End Page

6040 / 6055

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Prostatic Neoplasms, Castration-Resistant
  • Patient Preference
  • Pain
  • Nausea
  • Male
  • Humans
  • Fatigue
  • Cross-Sectional Studies
  • Bone Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. J., Mohamed, A. F., Tsai, J.-H., Karimi, M., Ning, N., Jayade, S., & Botteman, M. (2023). Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey. Cancer Med, 12(5), 6040–6055. https://doi.org/10.1002/cam4.5313
George, Daniel J., Ateesha F. Mohamed, Jui-Hua Tsai, Milad Karimi, Ning Ning, Sayeli Jayade, and Marc Botteman. “Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.Cancer Med 12, no. 5 (March 2023): 6040–55. https://doi.org/10.1002/cam4.5313.
George, Daniel J., et al. “Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey.Cancer Med, vol. 12, no. 5, Mar. 2023, pp. 6040–55. Pubmed, doi:10.1002/cam4.5313.
George DJ, Mohamed AF, Tsai J-H, Karimi M, Ning N, Jayade S, Botteman M. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey. Cancer Med. 2023 Mar;12(5):6040–6055.
Journal cover image

Published In

Cancer Med

DOI

EISSN

2045-7634

Publication Date

March 2023

Volume

12

Issue

5

Start / End Page

6040 / 6055

Location

United States

Related Subject Headings

  • Surveys and Questionnaires
  • Prostatic Neoplasms, Castration-Resistant
  • Patient Preference
  • Pain
  • Nausea
  • Male
  • Humans
  • Fatigue
  • Cross-Sectional Studies
  • Bone Neoplasms